In BRAF-mutant melanoma, combining BRAF/MEK inhibitions and immune checkpoint blockade shows a synergistic and potentially safe response and is currently being investigated, taking drug resistance mechanisms into consideration. Here, MAP2K7 is linked to melanoma.